BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 19035792)

  • 1. Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
    Bamborough P; Drewry D; Harper G; Smith GK; Schneider K
    J Med Chem; 2008 Dec; 51(24):7898-914. PubMed ID: 19035792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and optimization of pyrrolo[1,2-a]pyrazinones leads to novel and selective inhibitors of PIM kinases.
    Casuscelli F; Ardini E; Avanzi N; Casale E; Cervi G; D'Anello M; Donati D; Faiardi D; Ferguson RD; Fogliatto G; Galvani A; Marsiglio A; Mirizzi DG; Montemartini M; Orrenius C; Papeo G; Piutti C; Salom B; Felder ER
    Bioorg Med Chem; 2013 Dec; 21(23):7364-80. PubMed ID: 24139169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selectivity of kinase inhibitor fragments.
    Bamborough P; Brown MJ; Christopher JA; Chung CW; Mellor GW
    J Med Chem; 2011 Jul; 54(14):5131-43. PubMed ID: 21699136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity.
    Pogacic V; Bullock AN; Fedorov O; Filippakopoulos P; Gasser C; Biondi A; Meyer-Monard S; Knapp S; Schwaller J
    Cancer Res; 2007 Jul; 67(14):6916-24. PubMed ID: 17638903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computational proteomics of biomolecular interactions in the sequence and structure space of the tyrosine kinome: deciphering the molecular basis of the kinase inhibitors selectivity.
    Verkhivker GM
    Proteins; 2007 Mar; 66(4):912-29. PubMed ID: 17173284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New potent dual inhibitors of CK2 and Pim kinases: discovery and structural insights.
    López-Ramos M; Prudent R; Moucadel V; Sautel CF; Barette C; Lafanechère L; Mouawad L; Grierson D; Schmidt F; Florent JC; Filippakopoulos P; Bullock AN; Knapp S; Reiser JB; Cochet C
    FASEB J; 2010 Sep; 24(9):3171-85. PubMed ID: 20400536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design strategies for protein kinase inhibitors.
    Parang K; Sun G
    Curr Opin Drug Discov Devel; 2004 Sep; 7(5):617-29. PubMed ID: 15503864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural biology contributions to tyrosine kinase drug discovery.
    Cowan-Jacob SW; Möbitz H; Fabbro D
    Curr Opin Cell Biol; 2009 Apr; 21(2):280-7. PubMed ID: 19208462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and optimization of thieno[2,3-d]pyrimidines as B-Raf inhibitors.
    Packard GK; Papa P; Riggs JR; Erdman P; Tehrani L; Robinson D; Harris R; Shevlin G; Perrin-Ninkovic S; Hilgraf R; McCarrick MA; Tran T; Fleming Y; Bai A; Richardson S; Katz J; Tang Y; Leisten J; Moghaddam M; Cathers B; Zhu D; Sakata S
    Bioorg Med Chem Lett; 2012 Jan; 22(1):747-52. PubMed ID: 22137342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crystal structures of proto-oncogene kinase Pim1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma.
    Kumar A; Mandiyan V; Suzuki Y; Zhang C; Rice J; Tsai J; Artis DR; Ibrahim P; Bremer R
    J Mol Biol; 2005 Apr; 348(1):183-93. PubMed ID: 15808862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
    Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
    ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CHI's Fourth Annual Drug Discovery Chemistry Conference. Kinase inhibitor chemistry: charting the chemical space. 7-8 April 2009, San Diego, CA, USA.
    Seneci P
    IDrugs; 2009 Jun; 12(6):358-62. PubMed ID: 19517315
    [No Abstract]   [Full Text] [Related]  

  • 13. A general technique to rank protein-ligand binding affinities and determine allosteric versus direct binding site competition in compound mixtures.
    Annis DA; Nazef N; Chuang CC; Scott MP; Nash HM
    J Am Chem Soc; 2004 Dec; 126(47):15495-503. PubMed ID: 15563178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
    Gao Y; Davies SP; Augustin M; Woodward A; Patel UA; Kovelman R; Harvey KJ
    Biochem J; 2013 Apr; 451(2):313-28. PubMed ID: 23398362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based lead identification of ATP-competitive MK2 inhibitors.
    Barf T; Kaptein A; de Wilde S; van der Heijden R; van Someren R; Demont D; Schultz-Fademrecht C; Versteegh J; van Zeeland M; Seegers N; Kazemier B; van de Kar B; van Hoek M; de Roos J; Klop H; Smeets R; Hofstra C; Hornberg J; Oubrie A
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3818-22. PubMed ID: 21565500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A priori inference of cross reactivity for drug-targeted kinases.
    Fernandez A; Maddipati S
    J Med Chem; 2006 Jun; 49(11):3092-100. PubMed ID: 16722629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of 5-(1H-indol-5-yl)-1,3,4-thiadiazol-2-amines as potent PIM inhibitors.
    Wu B; Wang HL; Cee VJ; Lanman BA; Nixey T; Pettus L; Reed AB; Wurz RP; Guerrero N; Sastri C; Winston J; Lipford JR; Lee MR; Mohr C; Andrews KL; Tasker AS
    Bioorg Med Chem Lett; 2015 Feb; 25(4):775-80. PubMed ID: 25616902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based design of low-nanomolar PIM kinase inhibitors.
    Ishchenko A; Zhang L; Le Brazidec JY; Fan J; Chong JH; Hingway A; Raditsis A; Singh L; Elenbaas B; Hong VS; Marcotte D; Silvian L; Enyedy I; Chao J
    Bioorg Med Chem Lett; 2015 Feb; 25(3):474-80. PubMed ID: 25575657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The design, synthesis, and biological evaluation of PIM kinase inhibitors.
    Tsuhako AL; Brown DS; Koltun ES; Aay N; Arcalas A; Chan V; Du H; Engst S; Franzini M; Galan A; Huang P; Johnston S; Kane B; Kim MH; Laird AD; Lin R; Mock L; Ngan I; Pack M; Stott G; Stout TJ; Yu P; Zaharia C; Zhang W; Zhou P; Nuss JM; Kearney PC; Xu W
    Bioorg Med Chem Lett; 2012 Jun; 22(11):3732-8. PubMed ID: 22542012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of an Aurora kinase inhibitor through site-specific dynamic combinatorial chemistry.
    Cancilla MT; He MM; Viswanathan N; Simmons RL; Taylor M; Fung AD; Cao K; Erlanson DA
    Bioorg Med Chem Lett; 2008 Jul; 18(14):3978-81. PubMed ID: 18579375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.